Mark Heinen - Mar 1, 2023 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Chief Financial Officer
Signature
/s/ Mark Heinen
Stock symbol
BTTX
Transactions as of
Mar 1, 2023
Transactions value $
$0
Form type
4
Date filed
4/21/2023, 06:14 PM
Previous filing
Dec 2, 2022
Next filing
Dec 19, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Award $0 +54K +62.99% $0.00 140K Apr 5, 2023 Direct F1
holding BTTX Common Stock 2.28K Mar 1, 2023 By daughter

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Award $0 +28.6K $0.00 28.6K Mar 1, 2023 Common Stock 28.6K $1.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent restricted stock units (each, an "RSU") granted on April 5, 2023, which vest as to 1/2 of the shares on March 24, 2024 and the remaining shares vest on March 24, 2025, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The stock option vests as to 1/4 of the shares subject to the stock option on March 1, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on March 1, 2023.